- ►diabetesjournals.org JL Gross, MJ de Azevedo, SP Silveiro, LH … - Diabetes Care, 2005 - Am Diabetes Assoc Diabetic nephropathy is the leading cause of kidney disease in patients starting
renal replacement therapy and affects ∼40% of type 1 and type 2 diabetic
patients. It increases the risk of death, mainly from cardiovascular ... Cited by 214 - Related articles - All 18 versions
S Yamagishi, T Imaizumi - Current pharmaceutical design, 2005 - ingentaconnect.com Abstract: Diabetic vascular complication is a leading cause of end-stage renal
failure, acquired blindness, a variety of neuropathies and accelerated
atherosclerosis, which could account for disabilities and high mortality ... Cited by 123 - Related articles - All 3 versions
- ►endojournals.org BF Schrijvers, AS De Vriese, A Flyvbjerg - Endocrine reviews, 2004 - Endocrine Soc At present, diabetic kidney disease affects about 15–25% of type 1 and
30–40% of type 2 diabetic patients. Several decades of extensive research has
elucidated various pathways to be implicated in the development of diabetic ... Cited by 119 - Related articles - All 5 versions
- ►diabetesjournals.org KR Tuttle, GL Bakris, RD Toto, JB McGill, K … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—At baseline, urinary ACR was 764 ± 427 mg/g (means ± SD), and eGFR
was 70 ± 24 ml/min per 1.73 m 2 . Systolic and diastolic blood pressures were
135 ± 14 and 75 ± 9 mmHg, respectively. HbA 1c was 8.0 ± 1.2%. After 1 ... Cited by 95 - Related articles - BL Direct - All 5 versions
G Davì, A Falco, C Patrono - Antioxidants & Redox Signaling, 2005 - liebertonline.com T HE PREVALENCE OF DIABETES MELLITUS (DM), a metabolic disorder characterized by
high levels of blood glucose and insufficient secretion or action of endogenous
insulin, is increasing worldwide (8, 9). It represents a major cause of ... Cited by 69 - Related articles - All 4 versions
- ►nih.gov DA Salamanca, RA Khalil - Biochemical pharmacology, 2005 - Elsevier Vascular contraction is an important determinant of the peripheral vascular
resistance and blood pressure. The mechanisms underlying vascular smooth muscle
(VSM) contraction and the pathological changes that occur in hypertension ... Cited by 66 - Related articles - All 5 versions
- ►iovs.org LP Aiello, A Clermont, V Arora, MD Davis, MJ … - Investigative ophthalmology & visual science, 2006 - ARVO RESULTS. Twenty-nine persons aged 18 to 65 years with type 1 or 2 diabetes were
evaluated. The only treatment-emergent adverse event with a statistically
significant difference among treatment groups was abdominal pain, which was ... Cited by 64 - Related articles - BL Direct - All 5 versions
L Piconi, L Quagliaro, A Ceriello - Clinical Chemistry and Laboratory Medicine, 2003 - reference-global.com Increasing evidence in both experimental and clinical studies suggests that
there is a close link between hy- perglycemia, oxidative stress and diabetic
complica- tions. High blood glucose level determines overpro- duction of ... Cited by 55 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org J Menne, JK Park, M Boehne, M Elger, C … - Diabetes, 2004 - Am Diabetes Assoc Activation of protein kinase C (PKC) isoforms has been implicated in the
pathogenesis of diabetic nephropathy. We showed earlier that PKC-α is activated
in the kidneys of hyperglycemic animals. We now used PKC-α −/− mice to ... Cited by 52 - Related articles - BL Direct - All 4 versions
DJ Kelly, Y Zhang, G Moe, G Naik, RE Gilbert - Diabetologia, 2007 - Springer Abstract Aims/hypothesis Blockade of the renin–angiotensin system (RAS) with
either ACE inhibitors or angiotensin receptor blocker is a key therapeutic
strategy in slowing progression of diabetic nephropathy. Interruption of ... Cited by 46 - Related articles - BL Direct - All 3 versions
